恒古骨伤愈合剂内外并用治疗气滞血瘀型膝骨关节炎临床研究  

Clinical Study on Efficacy of Internal and External Linkage of the Osteoking on the Treatment of Knee Osteoarthritis with Qizhi Xueyu Syndrome

作　　者：华盛 欧梁 何瀚威 刘科[1] 白林寒 熊逸啸 汤祖宇 匡建军[2] HUA Sheng;OU Liang;HE Hanwei;LIU Ke;BAI Linhan;XIONG Yixiao;TANG Zuyu;KUANG Jianjun(Hunan University of Chinese Medicine,Changsha 410208,China;Hunan Academy of Chinese Medicine,Changsha 410006,China.)

机构地区：[1]湖南中医药大学,长沙410208 [2]湖南省中医药研究院

出　　处：《中国中医骨伤科杂志》2024年第8期39-43,47,共6页Chinese Journal of Traditional Medical Traumatology & Orthopedics

基　　金：湖南省自然科学基金项目(2023JJ60118);长沙市科技局重点项目(kh2201063);湖南省中医药研究院院级课题项目(202129)。

摘　　要：目的:观察恒古骨伤愈合剂内外并用治疗气滞血瘀型膝骨关节炎的临床疗效。方法:从2022年9月至2023年9月收集120例气滞血瘀型膝骨关节炎患者,按随机数字表法分为联合组、透药组、口服组、对照组(各30例)。联合组予恒古骨伤愈合剂口服联合中医定向透药治疗,透药组予恒古骨伤愈合剂中医定向透药治疗,口服组予恒古骨伤愈合剂口服治疗,对照组予塞来昔布治疗,以12d为1个疗程,治疗2个疗程。观察四组患者治疗前后临床疗效、视觉模拟量表(VAS)评分、西安大略和麦克马斯特大学(WOMAC)评分、中医证候评分、健康状况调查问卷(SF-36)评分及炎症因子水平变化。结果:治疗前,四组患者VAS评分、WOMAC评分、中医证候评分、SF-36评分及炎症因子比较,差异无统计学意义(P>0.05);治疗后联合组临床疗效、VAS评分、WOMAC评分、中医证候评分、SF-36评分及炎症因子的改善效果优于对照组、透药组、口服组,差异有统计学意义(P<0.05)。结论:恒古骨伤愈合剂内外并用治疗气滞血瘀型膝骨关节炎疗效突出,在改善临床症状、降低炎症因子水平、提高患者生活质量等方面效果显著。Objective:To observe the clinical efficacy of osteoking on the treatment of knee osteoarthritis with Qizhi Xueyu syndrome.Methods:120patients with Qizhi Xueyu syndrome knee osteoarthritis from September 2022to September 2023 were collected and divided into combination group,drug dialysis group,oral group and control group according to random number table method,with 30cases in each group.In the combination group,osteoking was given orally combined with traditional Chinese medicine(TCM)directional penetration therapy;in the drug dialysis group,osteoking was treated with directional drug penetration treatment;in the oral group,osteoking was given orally,and the control group was treated with celecoxib.12das one course of treatment and 2courses of treatment.The clinical efficacy,visual analogue scale(VAS)scores,Western Ontario and McMaster Universities(WOMAC)scores,TCM syndrome scores,36-Item Short Form Health Survey(SF-36)scores,and the level of inflammatory factors were observed before and after treatment in 4 groups.Results:There was no statistical difference in VAS scores,WOMAC scores,TCM syndrome scores,SF-36scores and inflammatory factors among 4groups before treatment(P>0.05).The VAS scores,WOMAC scores,TCM syndrome scores,SF-36scores and inflammatory factors in combination group were better than those in control group,drug penetration group and oral group after treatment(P<0.05).Conclusion:Osteoking has outstanding therapeutic efficacy on Qizhi Xueyu syndrome knee osteoarthritis,which can improve clinical symptoms,reduce the level of inflammatory factors and improve the quality of life of patients.

关 键 词：膝骨关节炎 气滞血瘀证 恒古骨伤愈合剂 中医定向透药疗法 内外并用 

分 类 号：R684.3[医药卫生—骨科学]